<DOC>
	<DOCNO>NCT02874248</DOCNO>
	<brief_summary>This study conduct evaluate effect single multiple therapeutic supratherapeutic oral dos E4/DRSP combination PK parameter , safety , tolerability cardiac repolarization , detect QT interval correct Fridericia 's formula ( QTcF ) .</brief_summary>
	<brief_title>E4/DRSP Single Multiple Dose PK Early QT Study</brief_title>
	<detailed_description>This randomize , double-blind , placebo-controlled , parallel , single center study healthy female subject . A total 42 female subject enrol 3 group 14 subject . A potential fourth group 14 healthy female subject may add . In group , subject randomize 2.5 1 ratio active ( n=10 ) placebo ( n=4 ) . Subjects receive single dose Day 1 , washout least 14 day , multiple dos 14 consecutive day Days 15 28 . Group 1 Group 2 may dose parallel . After completion Group 1 Group 2 , Dose Escalation Report ( DER ) , include PK data least 24 hour post-last dose , prepared Principal Investigator ( PI ) . Escalation plan dose level 60 mg E4/12 mg DRSP proceed safety tolerability dose level 15 mg E4/3 mg DRSP 30 mg E4/6 mg DRSP 24 hour post-last dose , acceptable PI Sponsor , deem necessary Independent Ethics Committee ( IEC ) follow review protocol , statement objection DER IEC . After completion Group 3 , second DER , include PK data , prepared PI . If Group 3 expect exposure level approximately 4 time exposure Group 1 achieve , treatment Group 3 well tolerate , additional group 14 subject may enrol , use dose level estimate result least 4 time exposure administration 15 mg E4/3 mg DRSP therapeutic dose .</detailed_description>
	<mesh_term>Drospirenone</mesh_term>
	<criteria>1 . Gender : Healthy female subject 2 . Age : 1850 year , inclusive 3 . Body mass index ( BMI ) : 18.035.0 kg/m2 4 . At screening , female subject must nonpregnant nonlactating , nonchildbearing potential 5 . Willing use doublebarrier method contraception screen 90 day follow visit . 6 . Willingness abstain alcohol grapefruit ( juice ) 48 hour prior admission clinical research center followup . 7 . Normal rest supine blood pressure pulse show clinically relevant deviation judge PI screen . 8 . Computerized ( 12lead ) ECG record without sign clinically relevant pathology screen 9 . Willing able sign ICF . 10 . Willing able comply study procedures 1 . Postmenopausal status 2 . History presence clinically relevant disease major system organ class ( e.g. , cardiovascular , pulmonary , renal , hepatic , gastrointestinal , reproductive , endocrinological , neurological , psychiatric orthopedic disease ) judge PI 3 . Condition hyperkalemia result renal insufficiency , hepatic dysfunction , adrenal insufficiency medication intake 4 . Previous participation current study 5 . Use : combine contraceptive ( i.e. , COC , Nuvaring® ) within 28 day prior first dose administration study completion progestogenonly contraceptive method ( e.g. , minipill , implant , hormonal intrauterine system ) within 28 day prior first dose administration study completion depot progestogen preparation injectable hormonal method contraception ( e.g. , DepoProvera® ) within 6 month prior first dose study completion 6 . Use : prescription drug herbal supplement act CYP3A4 function ( e.g. , St. John 's Wort ) within 28 day prior first study dose administration study completion overthecounter medication dietary supplement ( vitamin include ) within 14 day prior first study dose administration study completion . 7 . Use tobacco product within last 3 month prior first admission 8 . History alcohol abuse drug addiction ( include soft drug like cannabis product ) 9 . Positive drug screen 10 . Positive screen hepatitis B surface antigen ( HBsAg ) , hepatitis C virus ( HCV ) antibodies human immunodeficiency virus ( HIV ) 1 2 antibody 11 . Participation investigational drug study within 60 day prior first drug administration current study 12 . History relevant drug and/or food allergy 13 . Donation loss 100 mL blood within 60 day prior first drug administration . Donation loss 1.0 L blood 10 month prior first drug administration current study 14 . Significant and/or acute illness within 5 day prior first drug administration may impact safety assessment , judge PI 15 . History and/or family history congenital long QT syndrome , unexplained syncope additional risk Torsade de Pointes , sudden death 16 . History presence hormonerelated malignancy treat , whatever time onset . History malignancy organ system ( localize basal cell carcinoma skin ) , treat untreated , within past 5 year prior screen 17 . History migraine aura 18 . Any surgical medical condition could significantly alter absorption , distribution , metabolism , excretion drug , may jeopardize subject case participation study 19 . Contraindications use contraceptive steroid 20 . Sponsor employee clinical site personnel directly affiliate study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>